3-dimensional versus conventional laparoscopy for benign hysterectomy:protocol for a randomized clinical trial by Hoffmann, Elise et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
3-dimensional versus conventional laparoscopy for benign hysterectomy
Hoffmann, Elise; Bennich, Gitte; Larsen, Christian Rifbjerg; Lindschou, Jannie; Jakobsen,
Janus Christian; Lassen, Pernille Danneskiold
Published in:
B M C Women's Health
DOI:
10.1186/s12905-017-0434-7
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Hoffmann, E., Bennich, G., Larsen, C. R., Lindschou, J., Jakobsen, J. C., & Lassen, P. D. (2017). 3-dimensional
versus conventional laparoscopy for benign hysterectomy: protocol for a randomized clinical trial. B M C
Women's Health, 17, [76]. https://doi.org/10.1186/s12905-017-0434-7
Download date: 03. Feb. 2020
STUDY PROTOCOL Open Access
3-dimensional versus conventional
laparoscopy for benign hysterectomy:
protocol for a randomized clinical trial
Elise Hoffmann1* , Gitte Bennich2, Christian Rifbjerg Larsen3, Jannie Lindschou4, Janus Christian Jakobsen4,5
and Pernille Danneskiold Lassen2
Abstract
Background: Hysterectomy is one of the most common surgical procedures for women of reproductive age.
Laparoscopy was introduced in the 1990es and is today one of the recommended routes of surgery. A recent
observational study showed that operative time for hysterectomy was significantly lower for 3-dimensional
compared to conventional laparoscopy. Complication rates were similar for the two groups. No other observational
studies or randomized clinical trials have compared 3-dimensional to conventional laparoscopy in patients undergoing
total hysterectomy for benign disease.
The objective of the study is to determine if 3D laparoscopy gives better quality of life, less postoperative pain, less
per- and postoperative complications, shorter operative time, or a shorter stay in hospital and a faster return to work or
normal life, compared to conventional laparoscopy for benign hysterectomy.
Methods/design: The design is a randomised multicentre clinical trial. Participants will be 400 women referred for
laparoscopic hysterectomy for benign indications. Patients will be randomized to 3-dimensional or conventional
laparoscopic hysterectomy. Operative procedures will follow the same principles and the same standard whether the
surgeon’s vision is 3-dimensional or conventional laparoscopy. Primary outcomes will be the impact of surgery on
quality of life, assessed by the SF 36 questionnaire, and postoperative pain, assessed by a Visual Analogue scale for pain
measurement. With a standard deviation of 12 points on SF 36 questionnaire, a risk of type I error of 3.3% and a risk of
type II error of 10% a sample size of 190 patients in each arm of the trial is needed. Secondarily, we will investigate
operative time, time to return to work, length of hospital stay, and - and postoperative complications.
Discussion: This trial will be the first randomized clinical trial investigating the potential clinical benefits and harms of
3-dimensional compared to conventional laparoscopy. The results may provide more evidence regarding the future
place of 3-dimensional laparoscopy in the range of endoscopic approaches for benign hysterectomy.
Trial registration: This study is registered at ClinicalTrial.gov: NCT02610985 November 16th 2015. November 2015. The
regional Ethical committee approved it on the 12. November 2015, approval number: SJ-498. Data handling was
approved by the Danish Data Protection Agency: REG-109-2015 on the 13. November 2015.
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Background
Today it is generally accepted that the procedures of
choice for the removal of uterus on benign indication
should be laparoscopic or vaginal surgery. Both proce-
dures are associated with shorter hospital stay and faster
recovery compared to laparotomy [1–4]. Vaginal hyster-
ectomy has lower costs and in some studies, a lower
complication rate compared to laparoscopy [5]. In youn-
ger women without prolapse, however, the operation is
not as straightforward as in older women. Furthermore,
proper access to the pelvic cavity is not provided by the
vaginal route, which makes laparoscopy first choice
when the procedure involves adnexal surgery. In many
departments, adnexal surgery has become part of the
standard procedure for hysterectomy, since recent stud-
ies suggest that concomitant removal of the fallopian
tubes may decrease the risk of development of ovarian
and peritoneal cancer [6].
Despite promising results, adoption of the laparo-
scopic approach for benign hysterectomy has been slow.
A longer operating procedure, the requirement of ad-
vanced laparoscopic skills, and challenges in especially
obese patients have been cited as the main reasons [7].
Accordingly even today only a minor proportion of all
benign hysterectomies are performed laparoscopically in
European countries.
In 2005 the US Food and Drug Administration ap-
proved the Da Vinci robotic platform for gynaecologic
surgery. Due to improved dexterity, ergonomics, and a
3-dimensional imaging the technology was promoted to
overcome many of the limitations and drawbacks of con-
ventional laparoscopy [8]. Within few years, the number
of benign hysterectomies performed by robotic-assisted
laparoscopy showed a tremendous rise. Benefits com-
pared to conventional laparoscopy, however, have not
been reported [9]. On the contrary, a randomized trial
concludes that robotic assistance may lengthen operative
time for benign hysterectomy with an average of 77 min
compared to conventional laparoscopy [10].
Three-dimensional (3D) laparoscopy offers the same 3-
dimensional stereoscopic imaging as robotic surgery, but
in a conventional laparoscopic set-up with much lower
costs [11]. Although dexterity and ergonomics are theoret-
ically inferior to those of robotic surgery, docking of the
big and inconvenient patient robotic-cart is avoided, redu-
cing the number of operative steps. Furthermore, instru-
ments are held by the surgeon and not by robotic arms,
which means a preservation of the tactile sense. The place
of 3D laparoscopy in the range of endoscopic approaches
for benign hysterectomy, however, is not clear. An updated
literature search in PubMed and Embase, using Mesh
terms and the search string ““Imaging, Three-
Dimensional”” [Mesh]) AND ((““Hysterectomy”” [Mesh]) OR
laparoscopic hysterectomy) (19–02-2015), demonstrates
that data are sparse. No randomized trials exist, and only a
single retrospective study has been published within gynae-
cological surgery. In that study, operative time for hyster-
ectomy was significantly lower for 3D compared to
conventional laparoscopy. Complication rates were similar
for the two groups [12].
In conclusion, although laparoscopy is one of the rec-
ommended routes of surgery for benign hysterectomy,
the place of 3D laparoscopy in the range of endoscopic
approaches is not clear. Robotic surgery for hysterec-
tomy was introduced without evidence for the clinical
benefit, underlining the importance of clinical trials be-
fore implementation of new techniques. We expect that
3D- technology improves imaging and facilitates faster
and safer surgery, causing less pain, shorter recovery and
fewer postoperative complications.
Methods and design
Aim
The objective of the study is to determine if 3D laparos-
copy gives better quality of life, less postoperative pain,
less per- and postoperative complications, shorter opera-
tive time, or a shorter stay in hospital and a faster return
to work or normal life, compared to conventional lapar-
oscopy for benign hysterectomy.
Design
An investigator-initiated, blinded, randomized, clinical trial.
Setting
Roskilde University Hospital, Denmark.
Herlev University Hospital, Denmark.
Participants
Participants will be patients referred for laparoscopic
hysterectomy with or without bilateral salpingectomy or
bilateral salpingo-oophorectomy for benign indications.
Women not suitable for laparoscopic hysterectomy,
either because of [1] ultrasound appraisal of uterus
weight > 1000 g or [2] decision to carry out concomitant
prolapse surgery, will not be included. Further, patients
not able to read and understand Danish or give informed
consent are also excluded (Fig 1).
Interventions
In order to assess which mode of laparoscopy is more
favourable in a RCT, it is necessary to use similar and
well-defined procedures in all other areas around the
surgery. Therefore the preoperative information and pa-
tient education is standardized. Pre-emptive medication
is 8 mg dexamethasone, 2 g paracetamol, 400 mg
Ibumetin and 4 mg Ondacetron. Anaesthesia and post-
operative care is also standardized as well as the opera-
tive procedure.
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Standard preoperative assessment will be performed
together with transvaginal ultrasound estimating the size
of the uterus. Operative procedures will follow the
previously described “Gold standard” as follows: A
manipulator will be used in all patients to expose and
delineate different anatomical structures. For ligation
and dissection, a Thunderbeat® bipolar/ultrasound sea-
ling and cutting energy device will be used. After detach-
ment, uterus will be removed through the vaginal vault.
In case of a very narrow vagina combined with a
myomatous uterus it may be necessary to enlarge the
abdominal incision [13]. Morcellation or any other
destruction of the uterus inside the abdomen will not be
performed. The vaginal vault will be closed laparoscopic-
ally with a running Vicryl 2–0 suture or a barbed suture
V-lock® 2–0. Urinary catheter will be removed immedi-
ately after the operation. For postoperative pain relief,
the patients will be given sufentanil/Fentanyl in the re-
covery ward, and paracetamol, NSAID and in some
cases morphine in the gynaecological unit. After a few
hours on the recovery ward, they will return to the
gynaecological unit.
Data collection
Patients found suitable for participation will be informed
about the trial. If the patient wants to participate she will
fill out a quality of life questionnaire (SF 36-v2).
If willing to participate, and after instructions on how
to understand the questionnaire the patient completes
the SF-36 questionnaire in the preoperative assessment.
To reduce risk of bias at the 6 week postoperative tele-
phone interview, patient is re-introduced to and provided
with a copy of the SF 36 questionnaire at the time of
discharge; further, the research nurse is instructed to stay
Fig. 1 Participant flowchart in accordance with the CONSORT statement
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neutral at the telephone interview Randomization will be
performed in the morning of the operation day. A visual
analogue-scale (VAS) for pain scoring will be used when
the participants return to the gynaecological unit, 5 h
postoperatively. Hospital discharge will be considered
when the women are fully mobilized, urinating and pain
is controlled with milder oral analgesia. At discharge,
use of painkillers stronger than over-the-counter medi-
cine will be registered. The women will be asked to scale
their pain at a VAS score in the morning of the first 3
days after discharge. Six weeks after surgery, all patients
will receive a telephone call from a nurse, where a
SF-36-v2 questionnaire similar to that given preopera-
tively will be filled out. Pre-operative data is registered by
the doctor in the outpatient department record sheet,
Operative data by the surgeon in the operation record
sheet, and Postoperative data recorded by the nurse
surgeon in the discharge department record sheet. Any
readmission or complications causing readmission is reg-
istered by the doctor in the readmission sheet and will be
double-cheeked at the telephone interview. If readmitted
or treated at another hospital, this will be registered
(linked to personal identification number) at the national
patient register where all diagnoses are registered and
compiled, with the Hysterectomy Database ensuring no
complication will be overlooked.
Time to return to work or other normal life, use of
postoperative painkillers, and postoperative complica-
tions are noted by the nurse in the telephone interview
6 weeks after the operation (Table 1).
Randomization
Randomization will be performed centrally by The
Copenhagen Trial Unit. The allocation sequence will be
computer-generated and hidden from the investigators
and participants. The allocation ratio will be 1:1 and
stratification variables will be parity (0 or more), centers
(Roskilde or Herlev) and previous larger pelvic surgery
(yes/no).
Blinding
The surgeon operating the patient cannot, for obvious
reasons, be blinded. All patients and all caregivers
(except the surgeons) at the clinical departments will all
be blinded to trial intervention allocation. This is pos-
sible because patches on the stomach are placed the
same way regardless of conventional or 3D surgery. The
medical doctors evaluating the patient condition after
surgery and discharging the patients will also be blinded
to the trial intervention allocation.
Outcomes
Primary outcomes
(1)The impact of surgery on quality of life, assessed by
questionnaire (SF-36-v2, physical health score) at a
telephone interview 6 weeks postoperatively.
(2)Postoperative pain is assessed on a 100 mm
VAS-scale immediately after the operation at the
admission to post anaesthesia care unit (PACU) and
again 5 h postoperatively at gynaecological unit or at
the PACU if the patient unexpectedly has not
returned to gynaecological unit. These measures are
related to the patient lying quiet in the bed. Further
pain related to physical movements, will be reported in
the morning on day 1–3 postoperatively (longitudinal
data). Postoperative pain will also be related to the
analgesics given as we register the use of units of
morphine during the first 3 days.
Secondary outcomes
1. Proportion of participants with one or more of the
following major complications: organ lesion (injury
to bowel, bladder or ureter), vaginal hematoma
requiring intravenous AB, vaginal cuff rupture, port
hernia, reoperation due to bleeding, deep vein
thrombosis, pulmonary emboli or severe cardiac
complications and mechanic ileus. Conversion to
Table 1 Plan for obtaining data for both 2- and 3D hysterectomies
3D and conventional laparoscopic hysterectomy Enrolment in
outpatient clinic
Allocation and
operation
Discharge from
hospital
Telephone
interview
TIMEPOINT -t1 0 tx tx + 6 weeks
Baseline variables: height, weight, age, prior operations,
chronic pain, parity, estimated weight of uterus,
indication for operation, site. Quality of life by
SF-36 questionnaire
x x
Outcome variables 1: operating time, bleeding, concomitant
surgery, weight of uterus
x
Outcome variables 2: Postoperative pain and medication x x
Outcome variables 3: re-admissions, complications at home,
return to work, pain, return to daily living, unexpected
malignancy. Quality of life by SF-36 questionnaire
x x
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laparotomy is categorized as a major complication if
done for any other reason than to remove a large
uterus. In cases of conversion (mini-laparotomy) to
remove a large uterus, mini-laparotomy is not
considered a complication, and these patients are
pre-operatively informed of the risk of this event.
2. Proportion of participants with one or more of the
following of minor complications: Cystitis, smaller
vaginal cuff hematomas without need for
intravenous antibiotics, port infection orpain with
normal findings by vaginal ultrasound. All major and
minor adverse events will also be assessed separately.
3. The impact of surgery on quality of life, assessed by
questionnaire (SF-36-v2, mental health score).
4. Length of hospital stay (hours).
5. Operative time (defined as time from placement of
manipulator until last suture).
When calling the participants 6 weeks after their oper-
ation, we will also ask the women if and when they
returned to work and these reports will be summarized
for exploratory purposes.
Statistical analyses
The statistical analysis plan will be described in detail and
published in “BMC Medical Research Methodology”.
Our primary analyses for all outcomes will be adjusted
for the three stratification variables (number of previous
births (0 or more), centres (Roskilde or Herlev), and previ-
ous larger pelvic surgery (yes/no)). Our secondary analysis
for all outcomes will be adjusted for the three stratification
variables (see above) and other prognostic variables
(history of chronic pelvic pain (yes/no), co-morbidity,
enlarging of the abdominal incision to remove uterus (yes/
no), multiple adherences or need for other laparoscopic
procedures (yes/no). Full analysis will be carried out on
both groups, the intention-to-treat population (all ran-
domized participants) and observed cases.
Longitudinal data will be analysed using area under
the curve, continuous data will be analysed linear regres-
sion, dichotomous data will be analysed using logistic
regression, and survival data will be analysed using cox
regression. We will perform two sided statistical tests.
We will assess if the thresholds for statistical signifi-
cance and clinical significance are crossed using the five-
point procedure as suggested by Jakobsen et al. [14].
This procedure will include adjustments of thresholds
for significance according to the number of primary out-
comes (P-value threshold 0.033) and number of random-
ized participants. We will use a Bayes factor threshold
for significance of 0.1 based on the prior anticipated
intervention effect (see sample size calculation).
We will register if postoperative pathologic examin-
ation unexpectedly reveals cancer in a stage indicating
further surgery, or if surgery must be converted to open
surgery, for other reasons than to remove the uterus.
However, we expect such cases to be rare and we will
therefore include such participants in the primary
analysis. Sensitivity analyses will be performed if the pro-
portion of such cases is larger than expected.
Interim analyses and early stopping
After collection of data from 100 patients, an independent
safety and data monitoring committee will perform the
first interim analysis. This committee will thereafter advise
the steering committee and have the responsibility of
monitoring whether the trial should be stopped early or
continued until the sample size has been reached.
Sample size calculation and power estimation
Because our trial is designed with two primary out-
comes, our sample size calculation will be based on a
type 1 error of 3.3% [15].
Postoperative pain
We use a 100 mm VAS-score to assess pain. We con-
sider 10 mm as the minimal relevant difference with a
standard deviation of 20 mm and we accept a risk of
type I error of 3,3% and a risk of type II error of 10%.
This results in a sample size of 92 patients in each arm
of the trial.
SF 36 quality of life
We consider 4 points on the SF 36 quality of life as the
minimal relevant difference with a standard deviation of
12 points and we accept a risk of type I error of 3.3%
and a risk of type II error of 10%. This results in a sam-
ple size of 190 patients in each arm of the trial.
To be able to assess both of the co-primary outcomes,
we therefore chose 2 × 190 participants as our necessary
sample size.
Power estimations for secondary outcomes based on a
sample size of 2 × 190 participants
Major and minor complications
With a 5% acceptable risk of type I error, a proportion
of major complications in the control group of 12%, a
relative risk reduction of 20%, we will have 8.7% power
when assessing this outcome.
Length of hospital stay (hours)
With a sample size of 190 women in each arm of the
study, an alpha value of 5% and an average discharge of
48 h postoperatively versus 40 h, and a standard devi-
ation of 25 h, we have a power of 84%.
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Operative time
With a sample size of 190 women in each arm of the
study, an alpha value of 5% and an average operation
time of 101 min in the 2D group, and an operation time
of 90 min in the 3D group, and a standard deviation of
36 min, we have a power of 81%.
Missing data
All analyses are performed according to the intention-
to-treat principle. In case of less than 5% of missing data
for the randomized participants for primary and
secondary outcome, a complete case analysis will be per-
formed. In case of more than 5% missing data, multiple
imputations will be used to handle missing data. We will
additionally perform a sensitivity analysis using a best-
worst and worst-case scenario imputation [14].
Ethical considerations
When conducting medical intervention studies, ethical
considerations are always essential. This trial is important
because it is in the interest of the patient as well as the
health system to optimise surgery and minimise adverse
outcomes without an unreasonable increase in medical de-
vice expenses. Gynaecological examination and operation
are associated with discomfort to some extent, but patients
with relevant symptoms are undergoing these procedures
whether or not they are included in the trial. Furthermore,
available evidence suggests that 3D technology is at least as
good as the current technology. Thus, we provide the best-
proven standard of operation for both groups, and it is very
unlikely that we increase risks for the patients by perform-
ing 3D laparoscopy. Further all relevant information in-
cluding undesirable medical events occurring during the
clinical trial, presumably caused by the operation, will be
reported to the Danish Hysterectomy and Hysteroscopy
Database (DHHD).
We have designed the trial so that the risk of system-
atic errors and bias is minimised and therefore, data will
be meaningful and improve future laparoscopic surgery.
Discussion
The presented randomized trial is designed to investi-
gate the beneficial and harmful effects of 3-dimensional
versus conventional laparoscopy in patients undergoing
benign laparoscopic hysterectomy. A previous retro-
spective study suggests that operative time for hyst-
erectomy is significantly lower for 3D compared to
conventional laparoscopy [12]. Complication rates were
not statistically different, but this conclusion was limited
by a small number of patients in each group. So far, no
trials have examined whether 3D laparoscopy has an im-
pact on postoperative pain or quality of life after return
to daily activities.
3D laparoscopy offers a 3-dimensional stereoscopic im-
aging combined with preserved tactile sense as in a con-
ventional laparoscopic set-up, and 3D laparoscopy might
therefore refine and optimise surgery. However, we do not
know whether 3D laparoscopy offers clinical benefit com-
pared to conventional laparoscopic, whether the potential
beneficial effects are relevant for the patient, or whether
3D laparoscopy causes unexpected adverse effects.
The price of 3D laparoscopy is higher than for 2D
equipment, but lower than for robotic surgery. As med-
ical equipment is becoming increasingly sophisticated
and expensive, it is essential to determine whether 3D
has relevant effects in clinical practise before it is imple-
mented as part of the daily routine.
We hope that this trial will help place 3D laparoscopy
in the range of endoscopic approaches for benign
hysterectomy.
Trial strengths and limitations
This trial has a number of strengths. First, the randomized
design makes it possible to validly assess the effects of the
two surgical interventions. Second, the trial has a high de-
gree of external validity because we assess the effects of
operative procedures as they are performed in most
gynecological departments and we use two recruiting
centers. Third, the risk of systematic errors is reduced by
central randomization stratified for prognostic factors
[16, 17], blinding is used to the highest possible extent,
and data is analysed according to the intention-to-treat
principle. Fourth, in trials investigating operative proce-
dures it is often difficult to distinguish whether different ef-
fects of the operative techniques or varying skills of the
surgeon cause a supposed difference. In this present trial
the same experienced surgeons perform both the conven-
tional and 3D operations. This, together with the overall
low risk of bias of this trial, contributes to a high degree of
internal validity. Finally, we estimated a sample size ad-
justed for two primary outcomes using realistic anticipated
intervention effects and we performed power calculations
for all secondary outcomes, and we planned to adjust the
thresholds for significance if we do not reach the planned
sample size. This limits the risks of random error [14].
A limitation of this trial is that we will probably not be
able to detect a difference in complication rate between
the 2 arms of the trial. The overall low complication rate
following laparoscopic hysterectomy requires a large
sample size to detect a possible difference. We expect it
is more likely to demonstrate a difference in postopera-
tive pain or quality of life, two other relevant clinical
outcomes that have not previously been assessed follow-
ing 3D laparoscopic hysterectomy.
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